Skip To Content


Open conversations, knowledge sharing, and fresh ideas promote positive change and transparency

Thought leadership

Read more


Read more


Read more

Our latest blog posts, articles and podcasts 

Sharing information with the industry is an important part of our mission. Our subject matter experts translate today’s news into comprehensive informational pieces to help you better understand the impact of a recent industry update, trend, or issue.

May 02, 2023 · Clinical Team
On March 29, 2023, the U.S. Food and Drug Administration (FDA) approved Narcan® (naloxone hydrochloride) 4 mg Nasal Spray for over-the-counter (OTC), nonprescription, use. Read more...
May 01, 2023 · Optum Workers' Comp and Auto No-Fault
Cost savings programs can help insurers cut premium costs and attract clients in the notoriously difficult auto insurance line. Read more...
May 01, 2023 · Clinical Team
Akorn Operating Company LLC filed Chapter 7 bankruptcy and the company has ceased all operations, including the discontinuation of the quality activities of these marketed drug products. Read more...
April 20, 2023 · Clinical Team
On April 21, 2023, the ODG Drug Formulary (Appendix A) status will change for several medications within the topical analgesic and nonsteroidal anti-inflammatory (NSAID) classes. Read more...
April 14, 2023 · Public Policy & Regulatory Affairs Team
Brief updates on policy developments across the country, including Oregon workers’ comp updated rules, and Virginia workers’ comp cancer presumption and anxiety disorder bills. Read more...
April 06, 2023 · Clinical Team
Our Brand–Generic Pipeline lists new medications approved by the U.S. FDA and first-time generics or brand alternatives that potentially may be prescribed for the treatment of a workers’ compensation or auto injury. The Brand–Generic Pipeline for Q1 2023 is now available -- read it here. Read more...
<< Previous      Next >>
Page 2 of 7